Combined chemoimmunotherapy of metastatic melanoma: A single institution experience

Vincenzo Di Lauro, Simona Scalone, Nicoletta La Mura, Martina Zanetti, Paola Nigri, Andrea Freschi, Andrea Veronesi

Research output: Contribution to journalArticle

Abstract

The addition of cytokines, such as interferon α-2b and interleukin-2, to chemotherapy in metastatic melanoma has produced conflicting results in phase II and III trials. We report our experience with a chemoimmunotherapeutic regimen using subcutaneous cytokines. Twenty-eight patients with advanced melanoma (median age, 45 years; male to female ratio, 19:9) were treated. Doses were as follows: cisplatin, 20 mg/m2 intravenously (iv) days 1-4; vinblastine, 1.6 mg/m2 iv days 1-4; dacarbazine, 800 mg/ m 2 iv day 1; interferon α-2b, 5 MIU/m2 subcutaneously (sc) days 1-5; interleukin-2, 9 MIU/m2 sc days 1-5 and 8-12. Treatment was repeated every 3 weeks for a maximum of six cycles. The response was assessed after two cycles and toxicity at every cycle, according to World Health Organization (WHO) and National Cancer Institute (NCI) criteria, respectively. At a median follow-up of 8 months, only four patients (14%) were still alive. The overall response rate was 33%, with three (11%) complete responses lasting for 17, 14 and > 24 months. There were six (22%) partial responses and three stable disease. Amongst the responders, three patients progressed at the level of the central nervous system. The median time to progression and overall survival were 3.5 and 9 months, respectively. The most common grade 3-4 toxicity was neutropenia, reported in 25 of the 28 patients (92%). Only two patients (7%) experienced neutropenic fever. Thrombocytopenia grade 3-4 occurred in seven of the 28 patients (25%), with only one patient needing transfusional support One toxic death due to neutropenic fever occurred. It can be concluded that the chemoimmunotherapy schedule evaluated is active and may be considered for patients with metastatic melanoma who have a good performance status and a limited disease burden.

Original languageEnglish
Pages (from-to)209-212
Number of pages4
JournalMelanoma Research
Volume15
Issue number3
DOIs
Publication statusPublished - Jun 2005

Fingerprint

Melanoma
Interferons
Interleukin-2
Fever
Interleukin-9
Cytokines
Dacarbazine
National Cancer Institute (U.S.)
Vinblastine
Poisons
Neutropenia
Cisplatin
Appointments and Schedules
Central Nervous System
Drug Therapy
Survival

Keywords

  • Chemoimmunotherapy
  • Melanoma
  • Metastases

ASJC Scopus subject areas

  • Cancer Research
  • Dermatology

Cite this

Combined chemoimmunotherapy of metastatic melanoma : A single institution experience. / Di Lauro, Vincenzo; Scalone, Simona; La Mura, Nicoletta; Zanetti, Martina; Nigri, Paola; Freschi, Andrea; Veronesi, Andrea.

In: Melanoma Research, Vol. 15, No. 3, 06.2005, p. 209-212.

Research output: Contribution to journalArticle

Di Lauro, V, Scalone, S, La Mura, N, Zanetti, M, Nigri, P, Freschi, A & Veronesi, A 2005, 'Combined chemoimmunotherapy of metastatic melanoma: A single institution experience', Melanoma Research, vol. 15, no. 3, pp. 209-212. https://doi.org/10.1097/00008390-200506000-00011
Di Lauro, Vincenzo ; Scalone, Simona ; La Mura, Nicoletta ; Zanetti, Martina ; Nigri, Paola ; Freschi, Andrea ; Veronesi, Andrea. / Combined chemoimmunotherapy of metastatic melanoma : A single institution experience. In: Melanoma Research. 2005 ; Vol. 15, No. 3. pp. 209-212.
@article{c7b5e127c3754fb38f32e0882ed4dd6d,
title = "Combined chemoimmunotherapy of metastatic melanoma: A single institution experience",
abstract = "The addition of cytokines, such as interferon α-2b and interleukin-2, to chemotherapy in metastatic melanoma has produced conflicting results in phase II and III trials. We report our experience with a chemoimmunotherapeutic regimen using subcutaneous cytokines. Twenty-eight patients with advanced melanoma (median age, 45 years; male to female ratio, 19:9) were treated. Doses were as follows: cisplatin, 20 mg/m2 intravenously (iv) days 1-4; vinblastine, 1.6 mg/m2 iv days 1-4; dacarbazine, 800 mg/ m 2 iv day 1; interferon α-2b, 5 MIU/m2 subcutaneously (sc) days 1-5; interleukin-2, 9 MIU/m2 sc days 1-5 and 8-12. Treatment was repeated every 3 weeks for a maximum of six cycles. The response was assessed after two cycles and toxicity at every cycle, according to World Health Organization (WHO) and National Cancer Institute (NCI) criteria, respectively. At a median follow-up of 8 months, only four patients (14{\%}) were still alive. The overall response rate was 33{\%}, with three (11{\%}) complete responses lasting for 17, 14 and > 24 months. There were six (22{\%}) partial responses and three stable disease. Amongst the responders, three patients progressed at the level of the central nervous system. The median time to progression and overall survival were 3.5 and 9 months, respectively. The most common grade 3-4 toxicity was neutropenia, reported in 25 of the 28 patients (92{\%}). Only two patients (7{\%}) experienced neutropenic fever. Thrombocytopenia grade 3-4 occurred in seven of the 28 patients (25{\%}), with only one patient needing transfusional support One toxic death due to neutropenic fever occurred. It can be concluded that the chemoimmunotherapy schedule evaluated is active and may be considered for patients with metastatic melanoma who have a good performance status and a limited disease burden.",
keywords = "Chemoimmunotherapy, Melanoma, Metastases",
author = "{Di Lauro}, Vincenzo and Simona Scalone and {La Mura}, Nicoletta and Martina Zanetti and Paola Nigri and Andrea Freschi and Andrea Veronesi",
year = "2005",
month = "6",
doi = "10.1097/00008390-200506000-00011",
language = "English",
volume = "15",
pages = "209--212",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Combined chemoimmunotherapy of metastatic melanoma

T2 - A single institution experience

AU - Di Lauro, Vincenzo

AU - Scalone, Simona

AU - La Mura, Nicoletta

AU - Zanetti, Martina

AU - Nigri, Paola

AU - Freschi, Andrea

AU - Veronesi, Andrea

PY - 2005/6

Y1 - 2005/6

N2 - The addition of cytokines, such as interferon α-2b and interleukin-2, to chemotherapy in metastatic melanoma has produced conflicting results in phase II and III trials. We report our experience with a chemoimmunotherapeutic regimen using subcutaneous cytokines. Twenty-eight patients with advanced melanoma (median age, 45 years; male to female ratio, 19:9) were treated. Doses were as follows: cisplatin, 20 mg/m2 intravenously (iv) days 1-4; vinblastine, 1.6 mg/m2 iv days 1-4; dacarbazine, 800 mg/ m 2 iv day 1; interferon α-2b, 5 MIU/m2 subcutaneously (sc) days 1-5; interleukin-2, 9 MIU/m2 sc days 1-5 and 8-12. Treatment was repeated every 3 weeks for a maximum of six cycles. The response was assessed after two cycles and toxicity at every cycle, according to World Health Organization (WHO) and National Cancer Institute (NCI) criteria, respectively. At a median follow-up of 8 months, only four patients (14%) were still alive. The overall response rate was 33%, with three (11%) complete responses lasting for 17, 14 and > 24 months. There were six (22%) partial responses and three stable disease. Amongst the responders, three patients progressed at the level of the central nervous system. The median time to progression and overall survival were 3.5 and 9 months, respectively. The most common grade 3-4 toxicity was neutropenia, reported in 25 of the 28 patients (92%). Only two patients (7%) experienced neutropenic fever. Thrombocytopenia grade 3-4 occurred in seven of the 28 patients (25%), with only one patient needing transfusional support One toxic death due to neutropenic fever occurred. It can be concluded that the chemoimmunotherapy schedule evaluated is active and may be considered for patients with metastatic melanoma who have a good performance status and a limited disease burden.

AB - The addition of cytokines, such as interferon α-2b and interleukin-2, to chemotherapy in metastatic melanoma has produced conflicting results in phase II and III trials. We report our experience with a chemoimmunotherapeutic regimen using subcutaneous cytokines. Twenty-eight patients with advanced melanoma (median age, 45 years; male to female ratio, 19:9) were treated. Doses were as follows: cisplatin, 20 mg/m2 intravenously (iv) days 1-4; vinblastine, 1.6 mg/m2 iv days 1-4; dacarbazine, 800 mg/ m 2 iv day 1; interferon α-2b, 5 MIU/m2 subcutaneously (sc) days 1-5; interleukin-2, 9 MIU/m2 sc days 1-5 and 8-12. Treatment was repeated every 3 weeks for a maximum of six cycles. The response was assessed after two cycles and toxicity at every cycle, according to World Health Organization (WHO) and National Cancer Institute (NCI) criteria, respectively. At a median follow-up of 8 months, only four patients (14%) were still alive. The overall response rate was 33%, with three (11%) complete responses lasting for 17, 14 and > 24 months. There were six (22%) partial responses and three stable disease. Amongst the responders, three patients progressed at the level of the central nervous system. The median time to progression and overall survival were 3.5 and 9 months, respectively. The most common grade 3-4 toxicity was neutropenia, reported in 25 of the 28 patients (92%). Only two patients (7%) experienced neutropenic fever. Thrombocytopenia grade 3-4 occurred in seven of the 28 patients (25%), with only one patient needing transfusional support One toxic death due to neutropenic fever occurred. It can be concluded that the chemoimmunotherapy schedule evaluated is active and may be considered for patients with metastatic melanoma who have a good performance status and a limited disease burden.

KW - Chemoimmunotherapy

KW - Melanoma

KW - Metastases

UR - http://www.scopus.com/inward/record.url?scp=20544444401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20544444401&partnerID=8YFLogxK

U2 - 10.1097/00008390-200506000-00011

DO - 10.1097/00008390-200506000-00011

M3 - Article

C2 - 15917704

AN - SCOPUS:20544444401

VL - 15

SP - 209

EP - 212

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 3

ER -